ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety

Therapeutic Drug Monitoring

Volumn 30, Issue 5, 2008, Pages 628-633

  Gunes, Arzu ^a   Spina, Edoardo ^b,c   Dahl, Marja Liisa ^a   Scordo, Maria Gabriella ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UNIVERSITY OF MESSINA   (Italy)

^c IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

Author keywords

9 hydroxyrisperidone; ABCB1; CYP3A4; CYP3A5; Risperidone

Indexed keywords

PALIPERIDONE; RISPERIDONE; ABCB1 PROTEIN, HUMAN; CYP3A4 PROTEIN, HUMAN; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; ISOXAZOLE DERIVATIVE; MULTIDRUG RESISTANCE PROTEIN; PYRIMIDINE DERIVATIVE;

ADULT; ALLELE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOCHROME P450 2D6 GENE; CYTOCHROME P450 3A5 GENE; DRUG BLOOD LEVEL; FEMALE; GENE; GENE SEQUENCE; GENETIC CODE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; MALE; MONOTHERAPY; MULTIDRUG RESISTANCE PROTEIN 1 GENE; PRIORITY JOURNAL; SCHIZOPHRENIA; STEADY STATE; TREATMENT DURATION; BLOOD; COMPARATIVE STUDY; GENETICS; MIDDLE AGED;

ADULT; ALLELES; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; FEMALE; GENETIC VARIATION; GENOTYPE; HAPLOTYPES; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; P-GLYCOPROTEIN; P-GLYCOPROTEINS; POLYMORPHISM, GENETIC; PYRIMIDINES; RISPERIDONE;

EID: 55349137416     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181858ca9     Document Type: Article

References (42)

1. Leucht S, Wahlbeck K, Hamann J, et al. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet. 2003;361:1581-1589.
2. Meltzer HY, Zureick J. Negative symptoms in schizophrenia: a target for new drug development. Psychopharmacol Ser. 1989;7:68-77.
3. Yasui-Furukori N, Hidestrand M, Spina E, et al. Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metab Dispos. 2001;29:1263-1268.
4. Mannens G, Huang ML, Meuldermans W, et al. Absorption, metabolism, and excretion of risperidone in humans. Drug Metab Dispos. 1993;21: 1134-1141.
5. Fang J, Bourin M, Baker GB. Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn Schmiedebergs Arch Pharmacol. 1999;359:147-151.
6. Olesen Oy Licht RW, Thomsen E, et al. Serum concentrations and side effects in psychiatric patients during risperidone therapy. Ther Drug Monit. 1998;20:380-384.
7. Nyberg S, Eriksson B, Oxenstierna G, et al. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. Am J Psychiatry. 1999;156:869-875.
8. Spina E, Avenoso A, Facciola G, et al. Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. Psychopharmacology (Berl). 2001;153:238-243.
9. van Schaik RH, de Wildt SN, van Iperen NM, et al. CYP3A4-V polymorphism detection by PCR-restriction fragment length polymorphism analysis and its allelic frequency among 199 Dutch Caucasians. Clin Chem. 2000;46:1834-1836.
10. van Schaik RH, de Wildt SN, Brosens R, et al. The CYP3A4*3 allele: is it really rare? Clin Chem. 2001;47:1104-1106.
11. Wang A, Yu BN, Luo CH, et al. Ile118Val genetic polymorphism of CYP3A4 and its effects on lipid-lowering efficacy of simvastatin in Chinese hyperlipidemic patients. Eur J Clin Pharmacol. 2005;60:843-848.
12. Hesselink DA, van Shaik RHN, van der Heiden IP, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-I genes and pharmacokinerics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther. 2003;74:245-254.
13. Hesselink DA, van Gelder T, van Schaik RHN, et al. Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-I, CYP3A4 and CYP3A5 genes. Clin Pharmacol Ther. 2004;76:545-556.
14. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001;27:383-391.
15. van Schaik RH, van der Heiden IP, van den Anker JN, et al. CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem. 2002;48:1668-1671.
16. Marzolini C, Paus E, Buclin T, et al. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther. 2004;75:13-33.
17. Fromm MF. P-glycoprotein: a defense mechanism limiting oral bio-availability and CNS accumulation of drugs. Int J Clin Pharmacol Ther. 2000;38:69-74.
18. Boulton DW, DeVane CL, Liston HL, et al. In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci. 2002;71:163-169.
19. Nakagami T, Yasui-Furukori N, Saito M, et al. Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: in vivo evidence of involvement of P-glycoprotein in risperidone disposition. Clin Pharmacol Ther. 2005;78:43-51.
20. Kroetz DL, Pauli-Magnus C, Hodges LM, et al. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics. 2003;13:481-494.
21. Cascorbi I, Gerloff T, Johne A, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther. 2001;69:169-174.
22. Ito S, Ieiri I, Tanabe M, et al. Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenetics. 2001;11:175-184.
23. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA. 2000;97:3473-3478.
24. Horinouchi M, Sakaeda T, Nakamura T, et al. Significant genetic linkage of MDR1 polymorphisms at positions 3435 and 2677: functional relevance to pharmacokinetics of digoxin. Pharmacol Res. 2002;19:1581-1585.
25. Johne A, Kopke K, Gerloff T, et al. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther. 2002;72:584-594.
26. Verstuyft C, Schwab M, Schaeffeler E, et al. Digoxin pharmacokinetics and MDR1 genetic polymorphisms. Eur J Clin Pharmacol. 2003;58:809-812.
27. Mickley LA, Lee JS, Weng Z, et al. Genetic polymorphism in MDR-I: a tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors. Blood. 1998;91:1749-1756.
28. Monta Y, Sakaeda T, Horinouchi M, et al. MDR1 genotype-related duodenal absorption rate of digoxin in healthy Japanese subjects. Pharmacol Res. 2003;20:552-526.
29. Scordo MG, Spina E, Facciola G, et al. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (Berl). 1999;147:300-305.
30. Yasui-Furukori N, Mihara K, Takahata T, et al. Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-I genotypes. Br J Clin Pharmacol. 2004;57:569-575.
31. Yasui-Furukori N, Tsuchimine S, Saito M, et al. Association between major multidrug resistance 1 (MDR1) gene polymorphisms and plasma concentration of prolactin during risperidone treatment in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31: 1230-1234.
32. Leon J, Susce MT, Pan RM, et al. A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels. Pharmacopsychiatry. 2007;40: 93-102.
33. Xing Q, Gao R, Li H, et al. Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients. Pharmacogenomics. 2006;7:987-993.
34. Mirghani RA, Sayi J, Aklillu E, et al. CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population. Pharmacogenet Genomics. 2006;16:637-645.
35. Avenoso A, Facciola G, Salemi M, et al. Determination of risperidone and its major metabolite 9-hydroxyrisperidone in human plasma by reversed-phase liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl. 2000;746:173-181.
36. Mahatthanatrakul W, Nontaput T, Ridtitid W, et al. Rifampin, a cytochrome P450 3A inducer, decreases plasma concentrations of antipsychotic risperidone in healthy volunteers. J Clin Pharm Ther. 2007;32:161-167.
37. Jung SM, Kim KA, Cho HK, et al. Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients. Clin Pharmacol Ther. 2005;78:520-528.
38. Mihara K, Kondo T, Yasui-Furukori N, et al. Effects of various CYP2D6 genotypes on the steady-state plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, in Japanese patients with schizophrenia. Ther Drug Monit. 2003;25:287-293.
39. Vermeir M, Naessens I, Remmerie B, et al. Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans. Drug Met Dispos. 2008;36:769-779.
40. Wang JS, Ruan Y, Taylor RM, et al. The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein. Int J Neuropsychopharmacol. 2004;7:415-419.
41. Sai K, Kaniwa N, Itoda M, et al. Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan. Pharmacogenetics. 2003;13:741-757.
42. Melkersson KI. Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite. Hum Psychopharmacol. 2006;21:529-532.